地塞米松对重症COVID-19所致急性肾损伤的影响:一项多中心队列研究
这项在法国三个ICU开展的多中心研究纳入2020年3月至2021年8月因重症COVID-19入ICU的798例患者,排除入ICU前已存在AKI或已使用地塞米松者。第一波疫情未使用地塞米松、后续在入ICU时使用,形成两组。采用多因素病因特异性Cox模型(考虑ICU实践随时间变化)分析,地塞米松组AKI发生风险显著降低(HR 0.67;95CI 0.55-0.81),排除地塞米松给药至AKI发生间隔小于12小时的患者及纳入不同疫情波次的分析结果一致。作者认为这支持AKI的炎症性损伤可能可预防的假设。
要点
- 798例重症COVID-19 ICU患者中AKI发生率为75%(598/798),其中KDIGO 1、2、3期分别占38%、27%、35%,10%(61/598)需肾脏替代治疗。
- 地塞米松组较未使用组AKI发生风险显著降低(HR 0.67;95CI 0.55-0.81)。
- 排除地塞米松给药至AKI发生间隔小于12小时的患者后,结果一致。
- 纳入不同COVID-19疫情波次的分析中,地塞米松与AKI风险降低的关联仍一致。
- ICU死亡率为26%(208/798),中位SOFA评分4[3-6],53%(420/798)需有创机械通气。
适用人群与场景
- 2020年3月至2021年8月法国三个ICU收治的因重症COVID-19入ICU的成人患者(n=798)。
- 排除入ICU前已存在AKI或入ICU前已使用地塞米松的患者。
诊断标准与关键阈值
- AKI诊断采用KDIGO分期:KDIGO 1期266/598(38%)、2期163/598(27%)、3期210/598(35%)。
研究设计与关键结果
- 多中心队列研究,纳入798例重症COVID-19 ICU患者,平均年龄62.6±12.1岁,50%(402/798)有高血压,6%(46/798)有既往慢性肾病。
- 地塞米松组较未使用地塞米松组AKI发生风险显著降低(HR 0.67;95CI 0.55-0.81)。
- 排除地塞米松给药至AKI发生间隔小于12小时的患者后,结果一致。
- 纳入不同COVID-19疫情波次的分析中,地塞米松与AKI风险降低的关联仍一致。
- AKI总发生率75%(598/798),需肾脏替代治疗者占10%(61/598);ICU死亡率26%(208/798)。
证据类型、等级与局限
- 证据类型:多中心队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,地塞米松与重症COVID-19 ICU患者AKI风险降低相关,支持AKI的炎症性损伤可能可预防的假设。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Acute kidney injury (AKI) in intensive care unit (ICU) patients with severe COVID-19 is common (> 50%). A specific inflammatory process has been suggested in the pathogenesis of AKI, which could be improved by dexamethasone (DXM). In a small monocenter study (n = 100 patients), we reported a potential protective effect of DXM on the risk of AKI. This study aimed to investigate the preventive impact of DXM on AKI in a multicenter study of patients with severe COVID-19.
METHODS: We conducted a multicenter study in three French ICUs from March 2020 to August 2021. All patients admitted to ICU for severe COVID-19 were included. Individuals with preexistent AKI or DXM administration before admission to ICU were excluded. While never used during the first wave, DXM was used subsequently at ICU entry, providing two treatment groups. Multivariate Cause-specific Cox models taking into account changes in ICU practices over time, were utilized to determine the association between DXM and occurrence of AKI.
RESULTS: Seven hundred and ninety-eight patients were included. Mean age was 62.6 ± 12.1 years, 402/798 (50%) patients had hypertension, and 46/798 (6%) had previous chronic kidney disease. Median SOFA was 4 [3-6] and 420/798 (53%) required invasive mechanical ventilation. ICU mortality was 208/798 (26%). AKI was present in 598/798 (75%) patients: 266/598 (38%), 163/598 (27%), and 210/598 (35%) had, respectively, AKI KDIGO 1, 2, 3, and 61/598 (10%) patients required renal replacement therapy. Patients receiving DXM had a significantly decreased hazard of AKI occurrence compared to patients without DXM (HR 0.67; 95CI 0.55-0.81). These results were consistent in analyses that (1) excluded patients with DXM administration to AKI onset delay of less than 12 h, (2) incorporating the different 'waves' of the COVID-19 pandemic.
CONCLUSIONS: DXM was associated with a decrease in the risk of AKI in severe COVID-19 patients admitted to ICU. This supports the hypothesis that the inflammatory injury of AKI may be preventable.
参考来源
- Rubin S, Orieux A, Prezelin-Reydit M, et al. Impact of dexamethasone in severe COVID-19-induced acute kidney injury: a multicenter cohort study. Ann Intensive Care. 2024. PMID: 38349530. doi:10.1186/s13613-024-01258-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。